Johns Hopkins Medicine is launching a new research center aimed at how psychedelics and wellness uses a class illegal drugs affect health and changes in the user's consciousness.
Announced on Wednesday, September 4, the Center for Psychedelic and Consciousness Research is the first its kind in the US. A similar research center was created at Imperial College in London back in April, but it pales in comparison to the $17 million invested into Johns Hopkins' new venture in Baltimore. The funds were prfered entirely by a group private donors since federal funding for research surrounding illicit drugs is pretty much a nonstarter.
Studying LSD, psilocybin and other psychedelic compounds to determine how they affect various mental health problems, the hope is that researchers can focus on applications these drugs for treating everything from eating disorders and opioid addictions to Alzheimer’s disease and PTSD.
Roland Griffiths, a pressor behavioral biology at Hopkins’ School Medicine’s, will act as the center's director. “The center’s establishment reflects a new era research in therapeutics and the mind through studying this unique and remarkable class pharmacological compounds,” said Griffiths in a statement. “In addition to studies on new therapeutics, we plan to investigate creativity and well-being in healthy volunteers that we hope will open up new ways to support human thriving.”
Various studies over the years, many which came out Johns Hopkins School Medicine which has been studying hallucinogens since 2000, have conducted groundbreaking studies that explore the psychedelic possibilities.
Earlier this year, Dr. Matthew Johnson, an associate pressor at the University who will join as the new center's assistant director, conducted a study that suggests LSD and magic mushrooms can help people overcome alcohol dependency. Another Johns Hopkins scientist, Gül Döle, found groundbreaking insights into the biological mechanisms that MDMA triggers in the brain when it is used to treat PTSD.
“Our scientists have shown that psychedelics have real potential as medicine," said Dr. Paul B. Rothman, CEO Johns Hopkins Medicine in a statement. "This new center will help us explore that potential.”
Cameron is Mixmag's Jr. Editor. Follow him on Twitter here
Read this next!
Do you have to do drugs to enjoy dance music?
New study indicates that psychedelic drugs make people less violent
Magic mushrooms could help treat depression
Get the best Mixmag direct to your Facebook DMs